AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
Amgen: Buy The Dip Opportunity
Amgen offers a compelling value and income opportunity after a recent price dip, trading below historical valuation multiples. AMGN posted strong Q2 results with robust performance across its innov...
Amgen Inc. (AMGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Amgen Inc. (NASDAQ:AMGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT Company Participants Peter Griffith - Executive VP & CFO Kave Niksefat - Senior Vice ...
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic...
THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evalu...
If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today
Quick -- what were you doing back in September of 2022? Were you buying $10,000 of stock in Amgen (AMGN -1.17%)?
Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants & - Corporate Participant James E. Bradner - Executive Vice President of Research Developme...
Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates
Amgen (AMGN) came out with quarterly earnings of $6.02 per share, beating the Zacks Consensus Estimate of $5.26 per share. This compares to earnings of $4.97 per share a year ago.
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Amgen: A Defensive Biotech With Yield And Optionality
Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid, offering defensive characteristics, capital preservation, and yield over high-growth potential. The diversified product ...
Trading Rotation Kicks Off 2nd Half of 2025
Tech stocks lagged after a very strong first half of the year, while healthcare led the way.
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Here's Why Amgen (AMGN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Related Companies